Document is current
Any future updates will be listed below
-
Authors
Nishiyama, Takeyoshi
Tazawa, Hiroshi https://orcid.org/0000-0003-4658-1050
Nagai, Yasuo
Shoji, Ryohei
Kajiwara, Yoshinori
Hashimoto, Naoyuki https://orcid.org/0009-0003-9592-9209
Takahashi, Yosuke
Kikuchi, Satoru
Kuroda, Shinji
Ohara, Toshiaki
Noma, Kazuhiro https://orcid.org/0000-0002-5584-3908
Yoshida, Ryuichi
Umeda, Yuzo
Tanaka, Hiroyoshi Y. https://orcid.org/0000-0003-1494-7716
Kano, Mitsunobu R.
Masamune, Atsushi
Urata, Yasuo
Kagawa, Shunsuke https://orcid.org/0000-0002-3610-8211
Fujiwara, Toshiyoshi https://orcid.org/0000-0002-5377-6051
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP16K10596, JP21K07219, JP16H05416, JP19H03731)
Japan Agency for Medical Research and Development (17ck0106285h0001, 20ck0106569h0001)
- License Information
-
More Information
Article History
Received: 11 February 2025
Revised: 3 November 2025
Accepted: 11 November 2025
First Online: 28 November 2025
Competing interests
: YUr is the President & CEO of Oncolys BioPharma Inc. HT and TF are consultants of Oncolys BioPharma, Inc. The other authors have no potential conflicts of interest to disclose.
: All methods were performed in accordance with the relevant guidelines and regulations.
